Investigational drug · Phase 2
BS01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD).
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "BS01"
First trial start
2020
Feb 6, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BS01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinitis Pigmentosa
- Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "BS01" as an intervention, largest first.
Bionic Sight LLCIndustry
NCT07158775 · 40 participants (planned) · Start Jan 8, 2026 · Primary completion Dec 2027
Drug: BS01 · For: Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Sites: Edison, New Jersey
Bionic Sight LLCIndustry
NCT04278131 · 20 participants (planned) · Start Feb 6, 2020 · Primary completion Dec 30, 2026
Drug: BS01 · For: Retinitis Pigmentosa
Sites: Teaneck, New Jersey
Newest research
PubMed records naming it or its code names, newest first.
- Draft genomic sequence of lactic acid bacteria: Lactiplantibacillus plantarum LP48, Enterococcus durans ED01, and Bacillus subtilis BS01 with biotechnological potential.
García MD, Ruiz MJ, Medina Canalejo LM, et al. · Microbiol Resour Announc 2026
- Mechanisms of viability loss in dehydrated Metarhizium anisopliae blastospores.
Iwanicki NSA, Braga GÚL, Brancini GTP, et al. · Front Microbiol 2026
- Metabolomics aided by machine learning decodes adaptive remodeling of Bacillus biofilms in response to pasteurization stress.
Liang L, Wang P, Zhao X, et al. · NPJ Sci Food 2026
- The Impact of Probiotics on Clinical Symptoms and Peripheral Cytokines Levels in Parkinson's Disease: Preliminary In Vivo Data.
Magistrelli L, Contaldi E, Visciglia A, et al. · Brain Sci 2024
- Probiotics and Prebiotics Orally Assumed as Disease Modifiers for Stable Mild Atopic Dermatitis: An Italian Real-Life, Multicenter, Retrospective, Observational Study.
Colombo D, Rigoni C, Cantù A, et al. · Medicina (Kaunas) 2023
- Antimicrobial Polyketides from the Marine-Derived Fungus Spiromastix sp. SCSIO F190.
Cai C, Chen Y, Zhou L, et al. · J Nat Prod 2023
Also in development for Retinitis Pigmentosa
- CPK850Phase 21 trial
Novartis · Retinitis Pigmentosa
- famzeretcelhuman retinal progenitor cells, jCellPhase 21 trial
jCyte, Inc · Retinitis Pigmentosa
- KIO-301Phase 21 trial
Kiora Pharmaceuticals, Inc. · Retinitis Pigmentosa
- OCU400Phase 21 trial
Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis
- SPVN06Phase 21 trial
SparingVision · Retinitis Pigmentosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.